HC Wainwright reiterates Buy on Alnylam, lifts $455 target
HC Wainwright & Co. reiterated a Buy rating on Alnylam Pharmaceuticals and set a $455.00 price target, implying 89.9% upside from the Sep 18 close of $239.56.
HC Wainwright & Co. reiterated a Buy rating on Alnylam Pharmaceuticals and set a $455.00 price target, implying 89.9% upside from the Sep 18 close of $239.56.